Beximco Pharma Regulatory News (BXP)

30 Aug 2007 14:22

Beximco Pharmaceuticals Ltd30 August 2007 BEXIMCO PHARMACEUTICALS LTD. 30 August 2007 Beximco Pharma Commences Exports to Hong Kong Beximco Pharmaceuticals Ltd. ("BPL" or the "Company"), the leadingpharmaceutical manufacturer and the largest pharmaceutical exporter ofBangladesh has started supplying its medicines to Hong Kong, one of theregulated markets in the Asia-Pacific region, a company statement said today. The first consignment of medicines from BPL included seven products, namely,Azmasol(R) (Salbutamol) Inhaler, Alendon(R) (Alendronate Sodium 10 mg) Tablet,Alendon(R)-70 (Alendronate Sodium 70 mg) Tablet, Amdocal(R) 5 (Amlodipine 5 mg)Tablet, Amdocal(R) 10 (Amlodipine 10 mg) Tablet, Exovate(R) N (Combination ofNeomycin, Nystatin and Clobetasol) Cream and Terbex(R) (Terbinafine) Cream.These products will be distributed in Hong Kong by a highly acclaimedpharmaceutical marketing company of the region who has a long standingpartnership with renowned US and European pharmaceutical manufacturers. BPL has registered 15 products in Hong Kong and 12 others are expected toreceive marketing authorization soon. Mr. Nazmul Hassan, CEO of Beximco Pharma said: "In our global expansion program, the Asia-Pacific region is strategicallyimportant for us. Hong Kong is one of the most stringently regulated markets inthis region and achieving success in registering and exporting our productsthere is a major strategic breakthrough for BPL. I see this as a clear testimonynot only to our excellent product quality, but also to our capabilities to meetregulatory requirements of different markets and I hope this will fuel ourgrowth in this region in the coming years." For further enquiries please contact: Beximco Pharma Tel: +880 2 861 9151, ext.2080Nazmul Hassan, CEO Financial Dynamics Tel: +44 (0)20 7269 7169John Gilbert Libertas Capital Tel: +44 (0)20 7569 9650Aamir Quraishi/Andrew Hardy About Beximco Pharmaceuticals Limited Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sellsgeneric pharmaceutical formulation products, active pharmaceutical ingredientsand intravenous fluids. The Company also manufactures and markets its ownbranded generics for almost all diseases. The Company also undertakes contractmanufacturing for multinational pharmaceutical companies. The Company operatesfrom a 20 acre site in Dhaka and currently employs over 2,400 staff. The Company's products are sold to retail outlets, medical institutions andother pharmaceutical manufacturers in Bangladesh, in regional markets such asPakistan, Nepal, Bhutan, Cambodia and Myanmar and in other markets overseas,principally in East Africa and South East Asia, including Singapore. This information is provided by RNS The company news service from the London Stock Exchange